InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,745.37
(
0.40%
)
US TECH 100
19,588.00
(
0.80%
)
Dow Jones
42,175.11
(
0.62%
)
Brent Oil
70.95
(
-3.06%
)
Bitcoin
65,074.90
(
3.08%
)

Replies to post #2797 on Rexahn Pharmaceuticals, Inc. (REXN)

Replies to #2797 on Rexahn Pharmaceuticals, Inc. (REXN)
icon url

DorianGray

12/09/14 11:33 PM

#2798 RE: ttubular #2797

Up?
icon url

DorianGray

12/09/14 11:50 PM

#2799 RE: ttubular #2797

PS: We have three near-term catalysts over the next five months, between now and the end of Q1/15. They are: (1) the safety data from Archexin, (2) the safety data and initial efficacy data from the Phase 1b trial with RX-3117, and (3) the safety data and initial efficacy data from an ongoing Phase 1 trial with our third candidate in development, Supinoxin.